Advanced Life Sciences Announces Receipt of Nasdaq St...(are excited about the market opportunity...)
| HOME >> BIOLOGY >> TECHNOLOGY |
are excited about the market opportunity for cethromycin and are focused on delivering a comprehensive data report in the fall for Trial CL-05, the second pivotal Phase III study of the drug as a treatment for community acquired pneumonia (CAP)."
In the event that the Company does not regain compliance by September 12, 2007, Advanced Life Sciences will have the right to appeal a determination to delist its securities from the Nasdaq Global Market. The Company's securities would remain listed on the Nasdaq Global Market throughout the appeal process. Further, the Company can choose to apply to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market at any time throughout the appeal process, subject to approval by Nasdaq staff.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.
About Cethromycin
Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the
treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects during clinical trials.
The Company conducted two, pivotal Phase III clinical trials of
cethromycin for the treatment of mild-to-moderate CAP. In June of 2007,
Advanced Life Sciences released positive results from the first of these
two trials, Trial CL-06, which showed that cethromycin met primary and
secondary clinical endpoints. The Company believes that cethr
'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc. Copyright©2007 PR Newswire. |
Related biology technology :
1. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
2. Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option
3. 384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler
4. WARF expands license agreement with Advanced Cell Technology
5. Rockwells $1M gift to UWM will support advanced automation research
6. Advanced CIO: Technology execs must trumpet their success
7. FDA approves advanced digital mammography system
8. Tech Digest: Inacom; St. Michaels, St. Clares hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield
9. Wisconsins insurance companies use advanced IT to speed relief
10. $60 Million Available in Advanced Tech Competition
11. Advanced Life Sciences to Hit the Road For $30 Million in Funding
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |